Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | ITGAL | P20701 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
| ▸ | CD44 | P16070 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31020316 | 0.78 | OXTR (0.48) | OXTRGAANPSR1MAOBMAOA | |
| SCHEMBL186955 | 0.71 | — | — | |
| SCHEMBL30484685 | 0.71 | — | — | |
| SCHEMBL11352918 | 0.71 | PNMT (0.39) | GAANPSR1PNMTHTR2CAHR | |
| SCHEMBL519470 | 0.70 | OXTR (0.53) | OXTRGAANPSR1MAOBMAOA | |
| Formaldehyde SCHEMBL28963673 | 0.67 | OXTR (0.45) | OXTRGAANPSR1MAOBMAOA | |
| SCHEMBL879092 | 0.64 | OXTR (1.00) | OXTRGAANPSR1MAOBMAOA | |
| SCHEMBL21766748 | 0.64 | OXTR (0.47) | OXTRGAANPSR1MAOBMAOA | |
| SCHEMBL29356240 | 0.64 | OXTR (1.00) | OXTRGAANPSR1MAOBMAOA | |
| SCHEMBL17969084 | 0.64 | OXTR (1.00) | OXTRGAANPSR1MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 404 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023164680-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | RECLUDIX PHARMA, INC. (US) | 2023-08-31 | — | — | WO | claimed |
| EP-3774741-B1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2022-06-08 | — | — | EP | claimed |
| CN-109790164-B | Purine and 3-deazapurine analogues as choline kinase inhibitors | 内尔维亚诺医疗科学公司 | 2022-01-25 | — | — | CN | claimed |
| US-20210094941-A1 | Antimalarial Hexahydropyrimidine Analogues | UCB Biopharma SRL (BE) | 2021-04-01 | — | — | US | claimed |
| EP-3774741-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2021-02-17 | — | — | EP | claimed |
| CN-111936472-A | Anti-malarial hexahydropyrimidine analogues | UCB生物制药有限责任公司 | 2020-11-13 | — | — | CN | claimed |
| WO-2019192992-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB BIOPHARMA SPRL (BE) | 2019-10-10 | — | — | WO | claimed |
| US-20070123543-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | US | claimed |
| JP-2007513151-A | — | — | 2007-05-24 | — | — | JP | claimed |
| EP-1699803-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | claimed |
| WO-2005054249-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | WO | claimed |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-16 | — | — | US | claimed |
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-07-25 | — | — | US | claimed |
| EP-0995742-A1 | SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-26 | — | — | EP | claimed |
| US-20240217969-A1 | SUBSTITUTED PYRROLE CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2024-07-04 | — | — | US | disclosed |
| US-20240209439-A1 | NUCLEOTIDE ANALOGUE FOR SEQUENCING | BGI SHENZHEN (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240208994-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | US | disclosed |
| WO-1994029295-A1 | HETEROCYCLIC DERIVATIVES WITH IMMUNOMODULATING ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-12-22 | — | — | WO | disclosed |
| US-4252804-A | TRANQUILIZERS, ANTICONVULSANTS, MUSCLE RELAXANTS | METABIO-JOULLIE (FR) | 1981-02-24 | — | — | US | disclosed |
| US-4252804-A | TRANQUILIZERS, ANTICONVULSANTS, MUSCLE RELAXANTS | METABIO-JOULLIE (FR) | 1981-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209439-A1 | NUCLEOTIDE ANALOGUE FOR SEQUENCING | NT5C3B, NT5E, NUDT1 | OXTR 3538/4885GAA 1506/4885NPSR1 1397/4885 |
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | PDE2A, PDE3A, PDE12 | OXTR 723/4885GAA 171/4885NPSR1 463/4885 |
| US-20240208994-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, SERPINB1 | OXTR 2882/4885GAA 1244/4885NPSR1 2119/4885 |
| US-20070123543-A1 | Novel compounds | C1R, CHRM2, CHRM1 | OXTR 685/4885GAA 2499/4885NPSR1 42/4885 |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | PDE2A, PDE3A, PYGM | OXTR 1954/4885GAA 146/4885NPSR1 1699/4885 |
| US-20210094941-A1 | Antimalarial Hexahydropyrimidine Analogues | G6PD, DPYD, DHODH | OXTR 3582/4885GAA 3464/4885NPSR1 4248/4885 |
| US-20240217969-A1 | SUBSTITUTED PYRROLE CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | CDC7, CDK7, CDK17 | OXTR 4864/4885GAA 2466/4885NPSR1 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.